Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Jennifer Malin provides an overview of the need for increased access to care
John Hennessy discusses some of the challenges ACOs face in the oncology landscape
Randy Vogenberg provides an overview of some of the solutions providers are taking to ensure medication adherence.
Jennifer Mailn discusses the cost structure of novel therapeutics
Randy Vogenberg discusses the challenge of covering cancer care as survivorship increases
John Hennessy discusses the challenges in determining the cost value of cancer treatments
Ken Schaecher, MD, presents his own personal opinion on the multiple barriers to affordable high quality care for cancer patients.
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Page 1 of 9
Results 1 - 10 of 89
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME